Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03545971
Other study ID # CIBI310A101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 25, 2018
Est. completion date August 9, 2022

Study information

Verified date February 2023
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310, and in combination of sintilimab, in patients with advanced solid tumors(Ia) and advanced melanoma(Ib).


Description:

Phase Ia study will adopt the classical 3+3 dose escalation design. The starting dose is 0.3 mg/kg, followed by 3 dose cohorts (1mg/kg, 2mg/kg and 3mg/kg). Duration of dose limiting toxicity (DLT) observation period is 21 days. IBI310 treatment q3w, up to 3 cycles, will be provided to patients who complete DLT observation period. Efficacy will primarily be evaluated by RECIST v1.1. Patient safety will be monitored throughout the study. Pharmacokinetic/pharmacodynamics and immunogenicity will be assessed throughout the study. Phase Ib study will evaluate the tolerability and safety of IBI310 combined with Sintilimab in patients with advanced melanoma. Phase Ib of the study will begin after DLT observation is completed in certain dose cohorts.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date August 9, 2022
Est. primary completion date September 10, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Key Inclusion Criteria: 1. Patients with locally advanced, recurrent or metastatic solid tumors who failed standard treatment(applicable to the Ia period). 2. Patients with advanced, recurrent or metastatic melanoma confirmed by cytology or histology (applicable to the Ib period). 3. Signed written informed consent form and willing and able to comply with scheduled visits and other requirements of the study. 4. =18,and =70 years. 5. Life expectancy of at least 12 weeks. 6. At least 1 measurable lesion per RECIST v1.1(long axis>15mm or short axis>10mm) 7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1. 8. Patients of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study medication. 9. Adequate organ and bone marrow function. Key Exclusion Criteria: 1. Prior exposure to any anti-CTLA-4, anti-PD-1 or anti-PD-L1/L2 antibody. 2. Received any investigational agent within 4 weeks of the first dose of study medication. 3. Received last dose of anti-tumor therapy (chemotherapy, endocrine therapy, targeted therapy, tumor immunotherapy or arterial embolization) within 4 weeks of the first dose of study medication. 4. Received treatment with corticosteroids (>10mg daily prednisone equivalent) or other immunosuppressive medications within 4 weeks before the first dose of study medication. Nasal spray, inhalation, or other ways of topical corticosteroids or physiological doses of systemic corticosteroids are not included. 5. Received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period. 6. Active, known or suspected autoimmune disease or has a history of the disease within the last 2 years (Patients with vitiligo, psoriasis, alopecia or Grave's disease, hypothyroidism requiring hormone replacement, or type I diabetes mellitus only requiring insulin replacement, but not required systemic treatment in the last 2 years, are permitted to enroll) 7. Known primary immunodeficiency 8. Active tuberculosis 9. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation 10. Known allergy or hypersensitivity to any other monoclonal antibodies or IBI310 and/or any components used in their preparation. 11. Known acute or chronic active hepatitis B (HBV DNA positive and HBV DNA copies =1×103/ml or =200IU/ml) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection. Patients with HCV antibody positive but HCV RNA negative are permitted to enroll. 12. Patients with a history of interstitial lung disease 13. Uncontrolled third space effusion, eg. ascites or pleural effusion cannot be drained or controlled. 14. Women who are pregnant or nursing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IBI310
IBI310 is anti CTLA-4 antibody
Sintilimab
PD-1 monoclonal antibody

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Innovent Biologics (Suzhou) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary AEs Number of patients with treatment-related adverse events (AEs) up to 24 months after randomization
Secondary Pharmacokinetics:Cmax Maximum concentration(Cmax) of the drug after administration up to 24 months after randomization
Secondary pharmacodynamics:lipid parameters Change from baseline in lipid parameters up to 24 months after randomization
Secondary ADA Number of participants with anti-drug antibodies or neutralizing antibodies up to 24 months after randomization
Secondary Pharmacokinetics:AUC The area under the curve (AUC) of serum concentration of the drug after the administration up to 24 months after randomization
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT00962091 - Study of MLN8237 in Participants With Advanced Solid Tumors Phase 1